Navigation Links
VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
Date:8/4/2009

MOUNTAIN VIEW, Calif., Aug. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Canaccord Adams 29th Annual Global Growth Conference in Boston.

The VIVUS presentation will take place at the Intercontinental Hotel on Thursday, August 13, 2009 at 8:30 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://www.wsw.com/webcast/canaccord/vvus or http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

<
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIVUS to Present at the Needham and Company Life Sciences Conference
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS Reports First Quarter 2009 Financial Results and Highlights
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
8. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
9. Patent Awarded for a New X-ray Imaging Technology with Capability Unrealized with Present Day Radiological Modalities
10. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
11. Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... METTLER TOLEDO’s new line of XPE ... precision balances as well as automated dosing ... can carry out their daily weighing tasks worry free, ... deliver consistently reliable and compliant results, thanks to new ... of the biggest challenges in analytical and micro-analytical weighing ...
(Date:9/29/2014)... ANGELES , Sept. 29, 2014 ... biopharmaceutical research and development company specializing in oncology, ... Administration (FDA) has granted multiple Orphan Drug Designations ... three indications: glioblastoma multiforme (GBM), small cell lung ... version of the widely-used chemotherapeutic agent, doxorubicin. ...
(Date:9/27/2014)... in the peer-reviewed Journal of Animal Science ... crops has no impact on the health or productivity ... literature and field data sets, the article documents evidence ... GE crops are comparable with those of animals fed ... GE feed crops have become an increasing component of ...
Breaking Biology Technology:Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3New Line of XPE Balances from METLER TOLEDO is Designed for High Performance and Ease of Compliance 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5
... MILWAUKEE - Miller Brewing Co. ... its sourcing processes, consolidate purchases across six U.S. ... those processes, Procuri announced. , ,Procuri, ... such as Blue Cross and Blue Shield Association, ...
... from the University of Wisconsin-Madison and an international consortium ... the first astronomical images obtained by the Southern African ... to the largest optical telescope in the world. , ... built the telescope on a remote mountain plateau, 220 ...
... Wis. -- One of the greatest agricultural and evolutionary ... the answer may lie in a plot of corn on ... new life to ancient genetic material. , ,While many biologists ... of maize, others believe that the differences between teosinte and ...
Cached Biology Technology:Single gene controls key difference between maize and its wild ancestor 2Single gene controls key difference between maize and its wild ancestor 3
(Date:9/29/2014)... "human activities in this area of the world have contributed ... grown for use as a cooking oil and biofuel, while ... the most widely produced edible oil in the world, and ... soybean oil. , The environmental effects of such growth have ... crop, and the preferred method is fire. The clearing often ...
(Date:9/29/2014)... Mountain pine beetles get a bad rap, and ... pine trees over tens of millions of acres in ... , But contrary to popular belief, these pests ... like those that have recently swept through the region. ... the ecological severity of fires than these bark-boring beetles. ...
(Date:9/29/2014)... published online in Behavioral Brain Research provides ... as a result of chronic alcohol exposure that can ... Clinical assessments and research indicate that individuals with alcohol ... can occur when people are actively drinking, when they ... , "Sleep-wake disturbances can last for months, or ...
Breaking Biology News(10 mins):Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... As health professionals search for ways to combat the rise ... mother,s own eating habits and whether she views her ... on whether her child consumes enough fruits and vegetables. ... University,s College of Nursing looked at nearly 400 low-income women ...
... count, and that certainly holds true for the channels ... or molecules of a certain size to pass through, while ... capabilities of transmembrane proteins are highly prized for a number ... individual artificial channels of this size until now. ...
... Australia,s swamp bottlebrush, flowering plants are everywhere. Also ... land-based, plant life. New research published this week ... Sciences provides new insights into their genetic origin, ... diverse flowering plants more than 130 million years ago. ...
Cached Biology News:Mothers' diets have biggest influence on children eating healthy 2Tiny channels carry big information 2Tiny channels carry big information 3What 'pine' cones reveal about the evolution of flowers 2What 'pine' cones reveal about the evolution of flowers 3